BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Repotrectinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Repotrectinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06140836-2264@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:Repotrectinib: Phase 3 readout est. (NCT06140836)
DESCRIPTION:Repotrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Repotrectinib Versus Crizotinib in Participants With Locally Adv
 anced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive N
 on-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)\nEstimated primary completio
 n: 16 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 repotrectinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06140836
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06315010-2264@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Repotrectinib: Phase 2 readout est. (NCT06315010)
DESCRIPTION:Repotrectinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: R
 epotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Act
 ive Brain Metastasis\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/repotrectinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06315010
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03093116-2264@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Repotrectinib: Phase 1/2 readout est. (NCT03093116)
DESCRIPTION:Repotrectinib\, phase 1/2\, Solid Tumors.\nStudy: A Study of Re
 potrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring AL
 K\, ROS1\, or NTRK1-3 Rearrangements\nEstimated primary completion: 29 Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/repotrect
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03093116
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05004116-2264@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Repotrectinib: Phase 1/2 readout est. (NCT05004116)
DESCRIPTION:Repotrectinib\, phase 1/2\, Solid Tumors.\nStudy: A Study of Re
 potrectinib in Combination With Chemotherapy in Children and Young Adults 
 With Solid Tumor Cancer\nEstimated primary completion: August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/repotrectinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05004116
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06552234-2264@assetmemo.bio
DTSTAMP:20261121T004500Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Repotrectinib: Phase 2 readout est. (NCT06552234)
DESCRIPTION:Repotrectinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients W
 ith ROS1-rearranged Advanced NSCLC\nEstimated primary completion: Septembe
 r 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/repotrectinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 52234
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
